CINECA IRIS Institutional Research Information System
IRIS è la soluzione IT che facilita la raccolta e la gestione dei dati relativi alle attività e ai prodotti della ricerca. Fornisce a ricercatori, amministratori e valutatori gli strumenti per monitorare i risultati della ricerca, aumentarne la visibilità e allocare in modo efficace le risorse disponibili.
EnglishNampt is a promising target for the treatment of hematological malignancies. Here, we investigated the cytotoxic activity of APO866, a potent, reversible Nampt inhibitor, in primary acute myelogenous leukemia and in chronic lymphocytic leukemia cells. 10 nM APO866 exhibited limited killing of primary leukemia cells with specific death rates after four days of incubation that typically ranged between 10% and 50%. We conclude that, although APO866 is a promising agent for treating human leukemias, further studies are warranted to understand its mode of action, as well as its potential in combination treatments.
Scheda prodotto non validato
Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo
| Titolo: | APO866 activity in hematologic malignancies: a preclinical in vitro study. |
| Autori: | |
| Data di pubblicazione: | 2009 |
| Rivista: | |
| Abstract: | Nampt is a promising target for the treatment of hematological malignancies. Here, we investigated the cytotoxic activity of APO866, a potent, reversible Nampt inhibitor, in primary acute myelogenous leukemia and in chronic lymphocytic leukemia cells. 10 nM APO866 exhibited limited killing of primary leukemia cells with specific death rates after four days of incubation that typically ranged between 10% and 50%. We conclude that, although APO866 is a promising agent for treating human leukemias, further studies are warranted to understand its mode of action, as well as its potential in combination treatments. |
| Handle: | http://hdl.handle.net/11567/280265 |
| Appare nelle tipologie: | 01.01 - Articolo su rivista |
File in questo prodotto:
Copyright © 2021